Mike Panos Joins Insulet as Chief Commercial Officer

Insulet Corporation has appointed Mike Panos as executive vice president and chief commercial officer to lead the firm’s global commercial organization. He reports to President/CEO Ashley McEvoy.

“We have a significant growth opportunity in front of us, driven by strong clinical outcomes, customer-centric innovation, and expanding global adoption of automated insulin delivery as the standard of care in both type 1 and type 2 diabetes,” McEvoy said. “We are implementing strategies to strengthen our capabilities and structure to capture this opportunity and are thrilled to welcome Mike to Insulet. His expertise in building high-performing sales organizations and driving execution excellence will help elevate our commercial capabilities as we accelerate our growth.”

Panos has 30 years of commercial leadership experience in the medtech sector, most recently serving as leader of Sales Excellence at Stryker Corporation. Over his three-decade career at Stryker, he held multiple senior leadership roles, including president of the Trauma and Extremities Division and president of North America and Global R&D. Panos has a proven track record of building and scaling sales organizations, driving market expansion, and delivering sustained double-digit growth across highly competitive categories. He is widely recognized for developing top talent, instilling rigorous commercial discipline, and leading large, global teams to deliver both top-line growth and operational performance.

A Boston College graduate and long-time Boston-area resident, Panos brings deep ties to the region and local leadership experience to Insulet’s Massachusetts-based team.

At Insulet, Panos will help drive commercial strategy and execution across geographies, expand market access, and strengthen capabilities to support the company’s continued growth and reach, including expanding into new patient populations and care settings.

“I am honored to join Insulet at such a pivotal time in its journey,” Panos stated. “Insulet has built a strong foundation, with differentiated technology, compelling clinical outcomes, and a powerful brand. With significant opportunity to expand globally and reach more people with diabetes—including those not yet benefiting from automated insulin delivery technology—I look forward to partnering with the team to further strengthen commercial execution, support providers and patients, and help realize the full potential of the Omnipod platform.”

Insulet Corporation is a medical device company that simplifies life for patients with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides an alternative to traditional insulin delivery methods. With its simple, wearable design, the tubeless disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet’s flagship innovation, the Omnipod 5 Automated Insulin Delivery System, integrates with a continuous glucose monitor to manage blood sugar with no multiple daily injections or fingersticks, and can be controlled by a compatible U.S. personal smartphone or by the Omnipod 5 Controller. Insulet also leverages the design of its Pod by tailoring its Omnipod technology platform for delivering non-insulin subcutaneous drugs across other therapeutic areas.